Medpace Holdings Inc (NASDAQ:MEDP) major shareholder Medpace Investors, Llc sold 42,955 shares of the stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $120.79, for a total value of $5,188,534.45. Following the transaction, the insider now directly owns 7,280,452 shares of the company’s stock, valued at $879,405,797.08. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Medpace Investors, Llc also recently made the following trade(s):

  • On Tuesday, July 28th, Medpace Investors, Llc sold 214,499 shares of Medpace stock. The shares were sold at an average price of $127.23, for a total value of $27,290,707.77.
  • On Friday, July 24th, Medpace Investors, Llc sold 34,380 shares of Medpace stock. The shares were sold at an average price of $106.13, for a total value of $3,648,749.40.
  • On Wednesday, July 22nd, Medpace Investors, Llc sold 63,968 shares of Medpace stock. The shares were sold at an average price of $108.58, for a total value of $6,945,645.44.
  • On Monday, July 20th, Medpace Investors, Llc sold 37,044 shares of Medpace stock. The shares were sold at an average price of $105.39, for a total value of $3,904,067.16.
  • On Thursday, July 16th, Medpace Investors, Llc sold 15,273 shares of Medpace stock. The shares were sold at an average price of $103.70, for a total value of $1,583,810.10.
  • On Monday, July 13th, Medpace Investors, Llc sold 6,127 shares of Medpace stock. The shares were sold at an average price of $100.50, for a total value of $615,763.50.
  • On Thursday, July 9th, Medpace Investors, Llc sold 2,455 shares of Medpace stock. The shares were sold at an average price of $100.15, for a total value of $245,868.25.

MEDP opened at $119.35 on Friday. The stock has a fifty day moving average of $96.91 and a 200-day moving average of $88.75. The firm has a market capitalization of $4.23 billion, a P/E ratio of 39.31 and a beta of 1.22. Medpace Holdings Inc has a 12-month low of $58.72 and a 12-month high of $144.49. The company has a quick ratio of 0.89, a current ratio of 0.94 and a debt-to-equity ratio of 0.16.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, July 27th. The company reported $0.68 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.40 by $0.28. The company had revenue of $205.00 million during the quarter, compared to analyst estimates of $181.17 million. Medpace had a return on equity of 16.05% and a net margin of 12.11%. The company’s revenue for the quarter was down 4.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.81 earnings per share. On average, analysts expect that Medpace Holdings Inc will post 3.21 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wasatch Advisors Inc. lifted its holdings in shares of Medpace by 26.9% in the first quarter. Wasatch Advisors Inc. now owns 2,290,382 shares of the company’s stock valued at $168,068,000 after purchasing an additional 485,397 shares in the last quarter. State Street Corp increased its stake in shares of Medpace by 7.8% in the first quarter. State Street Corp now owns 859,618 shares of the company’s stock worth $63,079,000 after acquiring an additional 62,312 shares during the last quarter. Fuller & Thaler Asset Management Inc. increased its stake in shares of Medpace by 27.6% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 726,816 shares of the company’s stock worth $53,334,000 after acquiring an additional 157,308 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Medpace by 5.5% in the first quarter. Geode Capital Management LLC now owns 450,923 shares of the company’s stock worth $33,088,000 after acquiring an additional 23,691 shares during the last quarter. Finally, Ranger Investment Management L.P. increased its stake in shares of Medpace by 31.1% in the first quarter. Ranger Investment Management L.P. now owns 436,156 shares of the company’s stock worth $32,005,000 after acquiring an additional 103,591 shares during the last quarter. Institutional investors own 79.83% of the company’s stock.

MEDP has been the subject of a number of recent research reports. Credit Suisse Group increased their price objective on Medpace from $92.00 to $114.00 and gave the company an “outperform” rating in a research report on Tuesday. SunTrust Banks increased their price objective on Medpace from $95.00 to $124.00 and gave the company a “hold” rating in a research report on Wednesday. Wolfe Research downgraded Medpace from an “outperform” rating to a “peer perform” rating and set a $91.00 price objective for the company. in a research report on Wednesday, May 13th. Zacks Investment Research upgraded Medpace from a “hold” rating to a “strong-buy” rating and set a $137.00 price objective for the company in a research report on Saturday. Finally, Robert W. Baird upgraded Medpace from an “underperform” rating to a “neutral” rating and set a $83.00 price objective for the company in a research report on Monday, June 8th. Four analysts have rated the stock with a hold rating, two have given a buy rating and two have given a strong buy rating to the company’s stock. Medpace has an average rating of “Buy” and an average price target of $103.29.

Medpace Company Profile

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

Featured Story: How to invest using market indexes

Insider Buying and Selling by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.